ATF3和Runx2在乳腺癌中的表达及意义

doi:10.3760/cma.j.issn.1673-422X.2017.06.003

摘要/Abstract

摘要： 目的探讨激活转录因子3（ATF3）和成骨细胞特异性转录因子2（Runx2）在乳腺癌组织中的表达及临床意义。方法采用免疫组织化学法检测ATF3和Runx2在105例乳腺浸润性导管癌和相应癌旁乳腺组织中的表达情况，分析其与乳腺癌患者临床病理特征的关系。结果乳腺浸润性导管癌组ATF3和Runx2的阳性表达率分别为80.95%（85/105）和69.52%（73/105），显著高于癌旁乳腺组织的11.43%（12/105）和8.57%（9/105），差异均具有统计学意义（χ2=102.097，P=0.000；χ2=11.595，P=0.001）。ATF3和Runx2的表达与乳腺癌的组织学分级（χ2=14.623，P=0.001；χ2=24.891，P=0.000）、淋巴结转移（χ2=7.059，P=0.008；χ2=6.358，P=0.012）及pTNM分期相关（χ2=5.807，P=0.016；χ2=4.902，P=0.027），而与患者年龄（χ2=0.274，P=0.601；χ2=1.554，P=0.213）及肿瘤大小（χ2=2.476，P=0.290；χ2=5.261，P=0.072）无关。ATF3和Runx2在乳腺癌组织中的表达呈正相关（C=0.498，P=0.000）。结论ATF3和Runx2可能协同参与了乳腺癌的发生，而且ATF3和Runx2与乳腺癌的浸润、转移及临床分期有关，提示二者可能成为预测乳腺癌恶性程度和评估患者预后的重要指标。

关键词: 乳腺肿瘤, 免疫组织化学, 激活转录因子3, 成骨细胞特异性转录因子2

Abstract: ObjectiveTo study the expressions and clinical significances of activating transcription factor 3 (ATF3) and Runtrelated transcription factor 2 (Runx2) in breast carcinoma tissues. MethodsThe expressions of ATF3 and Runx2 were detected in 105 cases of primary breast invasive ductal carcinoma (IDC) and their matched paratumor breast tissues by immunohistochemistry. The relationships between the two transcription factors and the clinical pathological features of IDC patients were analyzed. ResultsThe positive expression rates of ATF3 and Runx2 in IDC group were 80.95% (85/105) and 69.52% (73/105) respectively, much higher than those in paratumor breast tissues 11.43% (12/105) and 8.57%(9/105), with statistically significant differences (χ2=102.097, P=0.000; χ2=11.595, P=0.001). ATF3 and Runx2 expressions showed significant relationships with histological grade (χ2=14.623, P=0.001; χ2=24.891, P=0.000), lymph node metastasis (χ2=7.059, P=0.008; χ2=6.358, P=0.012) and pTNM stage of IDC (χ2=5.807, P=0.016; χ2=4.902, P=0.027), while both were not correlated with patients′ age (χ2=0.274, P=0.601; χ2=1.554, P=0.213) and tumor size (χ2=2.476, P=0.290; χ2=5.261, P=0.072). There was a significant positive relationship between ATF3 and Runx2 in breast carcinoma (C=0.498, P=0.000). ConclusionThe overexpressions of ATF3 and Runx2 may participate in the tumorigenesis, invasion, metastasis and clinical stage of breast carcinoma, which suggests that they may be key factors to evaluate malignant degree and prognosis of breast carcinoma.

Key words: Breast neoplasms, Immunohistochemistry, Activating transcription factor 3, Runt-related transcription factor 2

黄丽娟,周炳娟,曹建江,张楠,陈红,马秋双,张金库. ATF3和Runx2在乳腺癌中的表达及意义[J]. 国际肿瘤学杂志, 2017, 44(6): 411-.

Huang Lijuan, Zhou Bingjuan, Cao Jianjiang, Zhang Nan, Chen Hong, Ma Qiushuang, Zhang Jinku. Expressions and clinical significances of ATF3 and Runx2 in breast carcinoma[J]. Journal of International Oncology, 2017, 44(6): 411-.

参考文献

［1］邓立峰, 张永胜, 崔红霞, 等. 子宫颈鳞癌组织中ATF3的表达及其临床病理学意义［J］. 临床与实验病理学杂志, 2015, 31(6): 703704. DOI: 10.13315/j.cnki.cjcep.2015.06.028. ［2］闵大六, 沈赞, 林峰, 等. Runx2和Ezrin基因在骨肉瘤组织中的表达及其临床意义［J］. 中国癌症杂志, 2012, 22(9): 685689. DOI: 10.3969/j.issn.10073969.2012.09.009. ［3］ Gold ES, Ramsey SA, Sartain MJ, et al. ATF3 protects against atherosclerosis by suppressing 25hydroxycholesterolinduced lipid body formation［J］. J Exp Med, 2012, 209(4): 807-817. DOI: 10.1084/jem.20111202. ［4］ Jang MK, Kim CH, Seong JK, et al. ATF3 inhibits adipocyte differentiation of 3T3L1 cells［J］. Biochem Biophys Res Commun, 2012, 421(1): 38-43. DOI: 10.1016/j.bbrc.2012.03.104. ［5］ Rose CL, Chakravarti N, Curry JL, et al. The utility of ATF3 in distinguishing cutaneous squamous cell carcinoma among other cutaneous epithelial neoplasms［J］. J Cutan Pathol, 2012, 39(8): 762-768. DOI: 10.1111/j.16000560.2012.01938.x. ［6］ Gargiulo G, Cesaroni M, Serresi M, et al. In vivo RNAi screen for BMI1 targets identifies TGFβ/BMPER stress pathways as key regulators of neuraland malignant gliomastem cell homeostasis［J］. Cancer Cell, 2013, 23(5): 660-676. DOI: 10.1016/j.ccr.2013.03.030. ［7］ Hackl C, Moser C, Lang S, et al. Activating transcription factor3 (ATF3) functions as a tumor suppressor in colon cancer and is upregulated upon heat shock protein 90 (Hsp90) inhibition［J］. Cancer Res, 2009, 69(9): 668. DOI: 10.1186/1471240710668. ［8］ Yuan X, Yu L, Li J, et al. ATF3 suppresses metastasis of bladder cancer by regulating gelsolinmediated remodeling of the actin cytoskeleton［J］. Cancer Res, 2013, 73(12): 3625-3637. DOI: 10.1158/00085472.CAN123879. ［9］ Jan YH, Tsai HY, Yang CJ, et al. Adenylate kinase4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor 3［J］. Cancer Res, 2012, 72(19): 51195129. DOI: 10.1158/00085472.CAN121842. ［10］ Feng JP, Sun QF, Wu TY, et al. Upregulation of ATF3 is correlated with prognosis and proliferation of laryngeal cancer by regulating Cyclin D1 expression［J］. Int J Clin Exp Pathol, 2013, 6(10): 2064-2070. ［11］ Cao H, Yang ZX, Jiang GQ. Expression and clinical significance of activating transcription factor 3 in human breast cancer［J］. Iran J Basic Med Sci, 2013, 16(11): 1151-1154. ［12］ Hao ZF, Ao JH, Zhang J, et al. ATF3 activates Stats phosphorylation through inhibition of p53 expression in skin cancer cells［J］. Asian Pac J Cancer Prev, 2013, 14(12): 7439-7444. ［13］ Kwok S, Rittling SR, Partridge NC, et al. Transforming growth factorb1 regulation of ATF3 and identification of ATF3 target genes in breast cancer cells［J］. J Cell Biochem, 2009, 108(2): 408-414. DOI: 10.1002/jcb.22267. ［14］ Yin X, Wolford CC, Chang YS, et al. ATF3, an adaptiveresponse gene, enhances TGF{beta} signaling and cancerinitiating cell features in breast cancer cells［J］. J Cell Sci, 2010, 123(20): 3558-3565. DOI: 10.1242/jcs.064915. ［15］ Wang AJ, Arantes S, Yan LQ, et al. The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis［J］. BMC Cancer, 2008, 8: 268. DOI: 10.1186/147124078268. ［16］ Onodera Y, Miki Y, Suzuki T, et al. Runx2 in human breast carcinoma: its potential roles in cancer progression［J］. Cancer Sci, 2010, 101(12): 2670-2675. DOI: 10.1111/j.13497006.2010.01742.x. ［17］ Owens TW, Rogers RL, Best SA, et al. Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer［J］. Cancer Res, 2014, 74(18): 5277-5286. DOI: 10.1158/00085472.CAN140053. ［18］ Barnes GL, Javed A, Waller SM, et al. Osteoblastrelated transcription factors Runx2(Cbfa1/AML3)and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells［J］. Cancer Res, 2003, 63(10): 2631-2637. ［19］ Zong JC, Wang X, Zhou X, et al. Gutderived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice［J］. Oncol Rep, 2016, 35(2): 739-748. DOI: 10.3892/or.2015.4430. ［20］ Fu JJ, Ke XQ, Tan SL, et al. The natural compound codonolactone attenuates TGFbeta 1mediated epithelialtomesenchymal transition and motility of breast cancer cells［J］. Oncol Rep, 2016, 35(1): 117-126. DOI: 10.3892/or.2015.4394. ［21］ Selvamurugan N, Kwok S, Partridge NC. Smad3 interacts with JunBand Cbfa1/Runx2 for transforming growth factor1stimulatedcollagenase3 expression in human breast cancer cells［J］. J Biol Chem, 2004, 279(26): 27764-27773. ［22］ Kwok S, Rittling SR, Partridge NC, et al. Transforming growth factorb1 regulation of ATF3 and identification of ATF3 target genes in breast cancer cells［J］. J Cell Biochem, 2009, 108(2): 408414. DOI: 10.1002/jcb.22267. ［23］ Gokulnath M, Partridge NC, Selvamurugan N. Runx2, a target gene for activating transcription factor3 in human breast cancer cells［J］. Tumor Biol, 2015, 36(3): 1923-1931. DOI: 10.1007/s132770142796x.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	廖利华, 王少洪, 陈洪才, 赵勇强. 细胞蜡块免疫组织化学与胸腔积液CRKL、MIC-1诊断恶性胸腔积液的价值[J]. 国际肿瘤学杂志, 2023, 50(2): 71-75.
[14]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[15]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.